Testing effectiveness (Phase 2)Ended earlyNCT06185543
What this trial is testing
A Phase 2, Randomized, Prospective Double-Blind, Single-Center, Placebo-controlled Study to Evaluate Safety, Tolerability, Target Engagement, and Efficacy of PrimeC in Patients With Mild to Moderate Alzheimer's Disease.
Who this might be right for
Alzheimer Disease
NeuroSense Therapeutics Ltd. 8